ADC Therapeutics (ADCT) EBT Margin (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly EBT Margin came in at 86.06% in Q2 2026, up 20797.0% year-over-year from N/an in Q2 2025, and up 45.57% quarter-over-quarter from 158.11% in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) EBT Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EBT Margin across 6 years of filings, most recently posting 86.06% for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 4.84% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -2.67% |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | -86.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -86.06% |
| Mar 31, 2026 | -158.11% |
| Sep 30, 2025 | -249.38% |
| Jun 30, 2025 | -294.03% |
| Mar 31, 2025 | -166.88% |
| Sep 30, 2024 | -236.24% |
| Jun 30, 2024 | -205.13% |
| Mar 31, 2024 | -253.70% |
| Sep 30, 2023 | -313.27% |
| Jun 30, 2023 | -273.30% |
| Mar 31, 2023 | -314.28% |
| Sep 30, 2022 | -67.24% |
| Jun 30, 2022 | -377.77% |
| Mar 31, 2022 | -38.35% |
| Sep 30, 2021 | -543.12% |
| Jun 30, 2021 | -1,923.64% |